カテゴリー： QYResearch, 世界, 医療/バイオ

薬剤耐性結核治療薬のグローバル市場2023年：第一類抗結核薬、第二類抗結核薬、その他

◆英語タイトル：Global Drug-Resistant Tuberculosis Treatment Market Research Report 2023

QYResearchが発行した調査報告書（QYR23MA8743）◆商品コード：QYR23MA8743
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2023年3月
◆ページ数：102
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本調査レポートは世界の薬剤耐性結核治療薬市場について調査・分析し、世界の薬剤耐性結核治療薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（第一類抗結核薬、第二類抗結核薬、その他）、用途別セグメント分析（病院薬局、オンライン薬局、小売薬局、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Sanofi、Novartis AG、Endo International plc、CMP Pharma、STI Pharma LLC、Akorn Incorporated、Lupin、Johnson & Johnson Services Inc.、Macleods Pharmaceuticals Ltd、Pfizer Inc、Hikma Pharmaceuticals PLC、Lannett、Mylan N.V.、Teva Pharmaceutical Industries Ltd、Fresenius Kabi AGなどが含まれています。世界の薬剤耐性結核治療薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、薬剤耐性結核治療薬市場規模を推定する際に考慮しました。

・薬剤耐性結核治療薬市場の概要
- 薬剤耐性結核治療薬のタイプ別セグメント
- 世界の薬剤耐性結核治療薬市場規模：タイプ別分析（第一類抗結核薬、第二類抗結核薬、その他）
- 薬剤耐性結核治療薬の用途別セグメント
- 世界の薬剤耐性結核治療薬市場規模：用途別分析（病院薬局、オンライン薬局、小売薬局、その他）
- 世界の薬剤耐性結核治療薬市場規模予測（2018年-2029年）

・薬剤耐性結核治療薬市場の成長トレンド
- 薬剤耐性結核治療薬の地域別市場規模（2018年-2029年）
- 薬剤耐性結核治療薬市場ダイナミクス
- 薬剤耐性結核治療薬の業界動向
- 薬剤耐性結核治療薬市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・タイプ別セグメント：第一類抗結核薬、第二類抗結核薬、その他
- 世界の薬剤耐性結核治療薬のタイプ別市場規模（2018年-2023年）
- 世界の薬剤耐性結核治療薬のタイプ別市場規模（2024年-2029年）

・用途別セグメント：病院薬局、オンライン薬局、小売薬局、その他
- 世界の薬剤耐性結核治療薬の用途別市場規模（2018年-2023年）
- 世界の薬剤耐性結核治療薬の用途別市場規模（2024年-2029年）

・薬剤耐性結核治療薬の地域別市場規模
- 北米の薬剤耐性結核治療薬市場規模（2018年-2029年）
- アメリカの薬剤耐性結核治療薬市場規模（2018年-2029年）
- ヨーロッパの薬剤耐性結核治療薬市場規模（2018年-2029年）
- アジア太平洋の薬剤耐性結核治療薬市場規模（2018年-2029年）
- 中国の薬剤耐性結核治療薬市場規模（2018年-2029年）
- 日本の薬剤耐性結核治療薬市場規模（2018年-2029年）
- 韓国の薬剤耐性結核治療薬市場規模（2018年-2029年）
- インドの薬剤耐性結核治療薬市場規模（2018年-2029年）
- オーストラリアの薬剤耐性結核治療薬市場規模（2018年-2029年）
- 中南米の薬剤耐性結核治療薬市場規模（2018年-2029年）
- 中東・アフリカの薬剤耐性結核治療薬市場規模（2018年-2029年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
Sanofi、Novartis AG、Endo International plc、CMP Pharma、STI Pharma LLC、Akorn Incorporated、Lupin、Johnson & Johnson Services Inc.、Macleods Pharmaceuticals Ltd、Pfizer Inc、Hikma Pharmaceuticals PLC、Lannett、Mylan N.V.、Teva Pharmaceutical Industries Ltd、Fresenius Kabi AG

・アナリストの観点/結論

・調査方法とデータソース

Highlights
The global Drug-Resistant Tuberculosis Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Drug-Resistant Tuberculosis Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Drug-Resistant Tuberculosis Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Drug-Resistant Tuberculosis Treatment in Hospital Pharmacy is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Drug-Resistant Tuberculosis Treatment include Sanofi, Novartis AG, Endo International plc, CMP Pharma, STI Pharma LLC, Akorn Incorporated, Lupin, Johnson & Johnson Services Inc. and Macleods Pharmaceuticals Ltd, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Drug-Resistant Tuberculosis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drug-Resistant Tuberculosis Treatment.
The Drug-Resistant Tuberculosis Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Drug-Resistant Tuberculosis Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drug-Resistant Tuberculosis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Sanofi
Novartis AG
Endo International plc
CMP Pharma
STI Pharma LLC
Akorn Incorporated
Lupin
Johnson & Johnson Services Inc.
Macleods Pharmaceuticals Ltd
Pfizer Inc
Hikma Pharmaceuticals PLC
Lannett
Mylan N.V.
Teva Pharmaceutical Industries Ltd
Fresenius Kabi AG
Segment by Type
First-Line Anti-TB Drugs
Second-Line Anti-TB Drugs
Others
Segment by Application
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drug-Resistant Tuberculosis Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drug-Resistant Tuberculosis Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 First-Line Anti-TB Drugs
1.2.3 Second-Line Anti-TB Drugs
1.2.4 Others
1.3 Market by Application
1.3.1 Global Drug-Resistant Tuberculosis Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacy
1.3.3 Online Pharmacy
1.3.4 Retail Pharmacy
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drug-Resistant Tuberculosis Treatment Market Perspective (2018-2029)
2.2 Drug-Resistant Tuberculosis Treatment Growth Trends by Region
2.2.1 Global Drug-Resistant Tuberculosis Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Drug-Resistant Tuberculosis Treatment Historic Market Size by Region (2018-2023)
2.2.3 Drug-Resistant Tuberculosis Treatment Forecasted Market Size by Region (2024-2029)
2.3 Drug-Resistant Tuberculosis Treatment Market Dynamics
2.3.1 Drug-Resistant Tuberculosis Treatment Industry Trends
2.3.2 Drug-Resistant Tuberculosis Treatment Market Drivers
2.3.3 Drug-Resistant Tuberculosis Treatment Market Challenges
2.3.4 Drug-Resistant Tuberculosis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drug-Resistant Tuberculosis Treatment Players by Revenue
3.1.1 Global Top Drug-Resistant Tuberculosis Treatment Players by Revenue (2018-2023)
3.1.2 Global Drug-Resistant Tuberculosis Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Drug-Resistant Tuberculosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drug-Resistant Tuberculosis Treatment Revenue
3.4 Global Drug-Resistant Tuberculosis Treatment Market Concentration Ratio
3.4.1 Global Drug-Resistant Tuberculosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drug-Resistant Tuberculosis Treatment Revenue in 2022
3.5 Drug-Resistant Tuberculosis Treatment Key Players Head office and Area Served
3.6 Key Players Drug-Resistant Tuberculosis Treatment Product Solution and Service
3.7 Date of Enter into Drug-Resistant Tuberculosis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drug-Resistant Tuberculosis Treatment Breakdown Data by Type
4.1 Global Drug-Resistant Tuberculosis Treatment Historic Market Size by Type (2018-2023)
4.2 Global Drug-Resistant Tuberculosis Treatment Forecasted Market Size by Type (2024-2029)
5 Drug-Resistant Tuberculosis Treatment Breakdown Data by Application
5.1 Global Drug-Resistant Tuberculosis Treatment Historic Market Size by Application (2018-2023)
5.2 Global Drug-Resistant Tuberculosis Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Drug-Resistant Tuberculosis Treatment Market Size (2018-2029)
6.2 North America Drug-Resistant Tuberculosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Drug-Resistant Tuberculosis Treatment Market Size by Country (2018-2023)
6.4 North America Drug-Resistant Tuberculosis Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drug-Resistant Tuberculosis Treatment Market Size (2018-2029)
7.2 Europe Drug-Resistant Tuberculosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Drug-Resistant Tuberculosis Treatment Market Size by Country (2018-2023)
7.4 Europe Drug-Resistant Tuberculosis Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size (2018-2029)
8.2 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drug-Resistant Tuberculosis Treatment Market Size (2018-2029)
9.2 Latin America Drug-Resistant Tuberculosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Drug-Resistant Tuberculosis Treatment Market Size by Country (2018-2023)
9.4 Latin America Drug-Resistant Tuberculosis Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size (2018-2029)
10.2 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Detail
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Drug-Resistant Tuberculosis Treatment Introduction
11.1.4 Sanofi Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2023)
11.1.5 Sanofi Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Detail
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG Drug-Resistant Tuberculosis Treatment Introduction
11.2.4 Novartis AG Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2023)
11.2.5 Novartis AG Recent Development
11.3 Endo International plc
11.3.1 Endo International plc Company Detail
11.3.2 Endo International plc Business Overview
11.3.3 Endo International plc Drug-Resistant Tuberculosis Treatment Introduction
11.3.4 Endo International plc Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2023)
11.3.5 Endo International plc Recent Development
11.4 CMP Pharma
11.4.1 CMP Pharma Company Detail
11.4.2 CMP Pharma Business Overview
11.4.3 CMP Pharma Drug-Resistant Tuberculosis Treatment Introduction
11.4.4 CMP Pharma Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2023)
11.4.5 CMP Pharma Recent Development
11.5 STI Pharma LLC
11.5.1 STI Pharma LLC Company Detail
11.5.2 STI Pharma LLC Business Overview
11.5.3 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Introduction
11.5.4 STI Pharma LLC Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2023)
11.5.5 STI Pharma LLC Recent Development
11.6 Akorn Incorporated
11.6.1 Akorn Incorporated Company Detail
11.6.2 Akorn Incorporated Business Overview
11.6.3 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Introduction
11.6.4 Akorn Incorporated Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2023)
11.6.5 Akorn Incorporated Recent Development
11.7 Lupin
11.7.1 Lupin Company Detail
11.7.2 Lupin Business Overview
11.7.3 Lupin Drug-Resistant Tuberculosis Treatment Introduction
11.7.4 Lupin Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2023)
11.7.5 Lupin Recent Development
11.8 Johnson & Johnson Services Inc.
11.8.1 Johnson & Johnson Services Inc. Company Detail
11.8.2 Johnson & Johnson Services Inc. Business Overview
11.8.3 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Introduction
11.8.4 Johnson & Johnson Services Inc. Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2023)
11.8.5 Johnson & Johnson Services Inc. Recent Development
11.9 Macleods Pharmaceuticals Ltd
11.9.1 Macleods Pharmaceuticals Ltd Company Detail
11.9.2 Macleods Pharmaceuticals Ltd Business Overview
11.9.3 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Introduction
11.9.4 Macleods Pharmaceuticals Ltd Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2023)
11.9.5 Macleods Pharmaceuticals Ltd Recent Development
11.10 Pfizer Inc
11.10.1 Pfizer Inc Company Detail
11.10.2 Pfizer Inc Business Overview
11.10.3 Pfizer Inc Drug-Resistant Tuberculosis Treatment Introduction
11.10.4 Pfizer Inc Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2023)
11.10.5 Pfizer Inc Recent Development
11.11 Hikma Pharmaceuticals PLC
11.11.1 Hikma Pharmaceuticals PLC Company Detail
11.11.2 Hikma Pharmaceuticals PLC Business Overview
11.11.3 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Introduction
11.11.4 Hikma Pharmaceuticals PLC Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2023)
11.11.5 Hikma Pharmaceuticals PLC Recent Development
11.12 Lannett
11.12.1 Lannett Company Detail
11.12.2 Lannett Business Overview
11.12.3 Lannett Drug-Resistant Tuberculosis Treatment Introduction
11.12.4 Lannett Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2023)
11.12.5 Lannett Recent Development
11.13 Mylan N.V.
11.13.1 Mylan N.V. Company Detail
11.13.2 Mylan N.V. Business Overview
11.13.3 Mylan N.V. Drug-Resistant Tuberculosis Treatment Introduction
11.13.4 Mylan N.V. Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2023)
11.13.5 Mylan N.V. Recent Development
11.14 Teva Pharmaceutical Industries Ltd
11.14.1 Teva Pharmaceutical Industries Ltd Company Detail
11.14.2 Teva Pharmaceutical Industries Ltd Business Overview
11.14.3 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Introduction
11.14.4 Teva Pharmaceutical Industries Ltd Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2023)
11.14.5 Teva Pharmaceutical Industries Ltd Recent Development
11.15 Fresenius Kabi AG
11.15.1 Fresenius Kabi AG Company Detail
11.15.2 Fresenius Kabi AG Business Overview
11.15.3 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Introduction
11.15.4 Fresenius Kabi AG Revenue in Drug-Resistant Tuberculosis Treatment Business (2018-2023)
11.15.5 Fresenius Kabi AG Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 薬剤耐性結核治療薬のグローバル市場2023年：第一類抗結核薬、第二類抗結核薬、その他(Global Drug-Resistant Tuberculosis Treatment Market Research Report 2023)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 腫瘍溶解性ウイルス薬物治療のグローバル市場2023年：フェーズ1、フェーズ2、その他
  • 治療抵抗性うつ病（TRD）治療の世界市場2022年～2029年：治療薬別、流通チャネル別、地域別
  • トリメチルアミン尿症治療のグローバル市場2023年：経口、注射

    • ◆H&Iグローバルリサーチのお客様（例）◆